(NASDAQ: BBIO) Bridgebio Pharma's forecast annual revenue growth rate of 17.74% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.84%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.63%.
Bridgebio Pharma's revenue in 2024 is $219,124,000.On average, 5 Wall Street analysts forecast BBIO's revenue for 2024 to be $46,228,600,768, with the lowest BBIO revenue forecast at $40,703,446,795, and the highest BBIO revenue forecast at $52,423,527,354. On average, 5 Wall Street analysts forecast BBIO's revenue for 2025 to be $39,319,525,843, with the lowest BBIO revenue forecast at $24,066,310,137, and the highest BBIO revenue forecast at $61,749,951,159.
In 2026, BBIO is forecast to generate $75,956,764,679 in revenue, with the lowest revenue forecast at $52,611,560,092 and the highest revenue forecast at $88,807,862,157.